Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Triggers for Atrial Fibrillation: The Role of Anxiety.

Severino P, Mariani MV, Maraone A, Piro A, Ceccacci A, Tarsitani L, Maestrini V, Mancone M, Lavalle C, Pasquini M, Fedele F.

Cardiol Res Pract. 2019 Feb 18;2019:1208505. doi: 10.1155/2019/1208505. eCollection 2019. Review.

2.

Aspirin-Dependent Effects on Purinergic P2Y1 Receptor Expression.

Massimi I, Alemanno L, Guarino ML, Guerriero R, Mancone M, Ceccacci A, Frati L, Angiolillo DJ, Pulcinelli FM.

Thromb Haemost. 2019 May;119(5):726-734. doi: 10.1055/s-0039-1678707. Epub 2019 Feb 13.

PMID:
30759486
3.

Reply to "Regarding the article of Ceccacci et al. (2016; 223: 54-55)" entitled "Role of MIBG scintigraphy in reverse Tako-tsubo cardiomyopathy: Confirming a pathophysiologic hypothesis".

Ceccacci A, Mancone M, Calcagno S, De Vincentis G, Sardella G, Fedele F.

Int J Cardiol. 2017 Feb 15;229:140. doi: 10.1016/j.ijcard.2016.12.016. Epub 2016 Dec 6. No abstract available.

PMID:
28034461
4.

Role of MIBG scintigraphy in reverse Tako-tsubo cardiomyopathy: Confirming a pathophysiologic hypothesis.

Ceccacci A, Mancone M, Calcagno S, De Vincentis G, Sardella G, Fedele F.

Int J Cardiol. 2016 Nov 15;223:54-55. doi: 10.1016/j.ijcard.2016.08.190. Epub 2016 Aug 9. No abstract available.

PMID:
27529592
5.

A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.

Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A, Colwell LF, Fay JF, Flores OA, Getty KL, Grobler JA, LaFemina RL, Markel EJ, Migliaccio G, Prhavc M, Stahlhut MW, Tomassini JE, MacCoss M, Hazuda DJ, Carroll SS.

Antimicrob Agents Chemother. 2004 Oct;48(10):3944-53.

6.

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Gennari N, Bisbocci M, Incitti I, Orsatti L, Harper S, Stansfield I, Rowley M, De Francesco R, Migliaccio G.

J Virol. 2003 Dec;77(24):13225-31.

7.

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro.

Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De Francesco R, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ, Flores OA.

J Biol Chem. 2003 Dec 5;278(49):49164-70. Epub 2003 Sep 8.

8.

In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.

Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, Narjes F, Muraglia E, Paonessa G, Koch U, De Francesco R, Steinkuhler C, Migliaccio G.

J Virol. 2003 Mar;77(6):3669-79.

9.

Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons.

Mottola G, Cardinali G, Ceccacci A, Trozzi C, Bartholomew L, Torrisi MR, Pedrazzini E, Bonatti S, Migliaccio G.

Virology. 2002 Feb 1;293(1):31-43.

10.

Tamarin alpha-interferon is active in mouse liver upon intramuscular gene delivery.

Aurisicchio L, Ceccacci A, La Monica N, Palombo F, Traboni C.

J Gene Med. 2001 Jul-Aug;3(4):394-402.

PMID:
11529669
11.

Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection.

Meola A, Sbardellati A, Bruni Ercole B, Cerretani M, Pezzanera M, Ceccacci A, Vitelli A, Levy S, Nicosia A, Traboni C, McKeating J, Scarselli E.

J Virol. 2000 Jul;74(13):5933-8.

Supplemental Content

Loading ...
Support Center